Compare ALEMBIC LTD with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs CIPLA - Comparison Results

ALEMBIC LTD     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD CIPLA ALEMBIC LTD/
CIPLA
 
P/E (TTM) x 67.8 23.3 291.1% View Chart
P/BV x 2.4 2.4 101.2% View Chart
Dividend Yield % 0.4 0.7 62.6%  

Financials

 ALEMBIC LTD   CIPLA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
CIPLA
Mar-19
ALEMBIC LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs72678 10.6%   
Low Rs34484 7.0%   
Sales per share (Unadj.) Rs4.7198.2 2.4%  
Earnings per share (Unadj.) Rs6.118.5 33.0%  
Cash flow per share (Unadj.) Rs6.235.0 17.9%  
Dividends per share (Unadj.) Rs0.203.00 6.7%  
Dividend yield (eoy) %0.40.5 73.1%  
Book value per share (Unadj.) Rs40.7186.3 21.8%  
Shares outstanding (eoy) m267.03805.70 33.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x11.32.9 384.4%   
Avg P/E ratio x8.731.4 27.7%  
P/CF ratio (eoy) x8.516.6 51.1%  
Price / Book Value ratio x1.33.1 41.8%  
Dividend payout %3.316.2 20.2%   
Avg Mkt Cap Rs m14,139468,031 3.0%   
No. of employees `000NA22.6 0.0%   
Total wages/salary Rs m20728,565 0.7%   
Avg. sales/employee Rs ThNM7,053.1-  
Avg. wages/employee Rs ThNM1,261.5-  
Avg. net profit/employee Rs ThNM659.1-  
INCOME DATA
Net Sales Rs m1,255159,710 0.8%  
Other income Rs m3704,766 7.8%   
Total revenues Rs m1,625164,475 1.0%   
Gross profit Rs m11130,973 0.4%  
Depreciation Rs m3813,263 0.3%   
Interest Rs m21,684 0.1%   
Profit before tax Rs m44220,791 2.1%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m245,695 0.4%   
Profit after tax Rs m1,63014,924 10.9%  
Gross profit margin %8.919.4 45.6%  
Effective tax rate %5.427.4 19.8%   
Net profit margin %129.89.3 1,389.5%  
BALANCE SHEET DATA
Current assets Rs m1,867124,266 1.5%   
Current liabilities Rs m59137,715 1.6%   
Net working cap to sales %101.654.2 187.6%  
Current ratio x3.23.3 95.9%  
Inventory Days Days9491 104.0%  
Debtors Days Days7495 77.5%  
Net fixed assets Rs m1,791105,190 1.7%   
Share capital Rs m5341,611 33.1%   
"Free" reserves Rs m10,324148,511 7.0%   
Net worth Rs m10,858150,123 7.2%   
Long term debt Rs m4138,301 0.1%   
Total assets Rs m11,591239,633 4.8%  
Interest coverage x260.913.3 1,955.0%   
Debt to equity ratio x00.3 1.5%  
Sales to assets ratio x0.10.7 16.2%   
Return on assets %14.16.9 203.1%  
Return on equity %15.09.9 151.0%  
Return on capital %15.211.8 128.3%  
Exports to sales %1.534.7 4.5%   
Imports to sales %21.00-   
Exports (fob) Rs m1955,419 0.0%   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1957,410 0.0%   
Fx outflow Rs m26419,041 1.4%   
Net fx Rs m-24438,368 -0.6%   
CASH FLOW
From Operations Rs m23616,911 1.4%  
From Investments Rs m-224-16,687 1.3%  
From Financial Activity Rs m-27-3,487 0.8%  
Net Cashflow Rs m-15-3,451 0.4%  

Share Holding

Indian Promoters % 64.0 16.0 400.0%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.2 12.2 1.6%  
FIIs % 9.7 23.7 40.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 26.1 26.2 99.6%  
Shareholders   54,701 161,166 33.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  TTK HEALTHCARE  SHASUN PHARMA  

Compare ALEMBIC LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Oct 18, 2019 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 8-QTR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS